Furthermore, the observation that TP-0903 retains activity in NRAS mutant AML, irrespective of FLT3-ITD status, merits further investigation into the activity of TP-0903 in other forms of drug-resistant AML due to RAS pathway mutations. This evidence concerns the gene NRAS and acute myeloid leukemia.